[1] | A.Lukyanov†, T. Elbayoumi†, A.Chakilam, V,Torchilin, "Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody". Journal of Controlled Release, 2004;100(1):135-44. (†ANL&TAE equally contributed in this study) |
[2] | L. Mu, T. Elbayoumi, V. Torchilin, "Mixed micelles made of polyethyleneglycol-phosphatidylethanolamine conjugate and D-α-tocopheryl polyethylene glycol 1000 succinate as carriers for camptothecin". International Journal of Pharmaceurics, 2005; 306 (1-2):142-9. |
[3] | T. Elbayoumi and V. Torchilin, "Enhanced accumulation of long-circulating liposomes modified with nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: Gamma-imaging studies". European Journal of Nuclear Medicine and Molecular Imaging, 2006; 33(10):196-205. |
[4] | T. Elbayoumi, S. Pabbas, A. Ruby, and V. Torchilin, "Anti-nucleosome antibody modified liposomes and lipid-core micelles for tumor targeted delivery of therapeutic and diagnostic agents". Journal of Liposome Research, 2007; 17(1):1-14. |
[5] | T. Elbayoumi and V. Torchilin, "Internalization of anti-nucleosome antibody targeted Doxorubicin PEG-liposomes induces enhanced cytotoxicity against various tumour cell lines". European Journal of Pharmaceutical Sciences, 2007; 32(3):159-68. |
[6] | T. Elbayoumi and V. Torchilin, "Tumor-specific antibody-mediated targeted delivery of Doxil® reduces the manifestation of auricular erythema side effect in mice". International Journal of Pharmaceutics, 2008; 357(1-2):272-9. |
[7] | T. Elbayoumi and V. Torchilin, "Tumor-targeted immuno-liposomes for Cancer therapy and imaging" Journal of Pharmaceutical Innovations, 2008; (4):2-7. |
[8] | T. Elbayoumi and V.Torchilin, "Liposomes for enhanced delivery of thrombolytic agents", Expert Opinion in Drug Delivery, 2008; 5(11):1185-98. |
[9] | T. Elbayoumi and V. Torchilin, "Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice". Molecular Pharmaceutics, 2009; 6(1):246-54. |
[10] | T. Elbayoumi and V. Torchilin, "Tumor-targeted nanomedicines: Enhanced anti-tumor efficacy in vivo of doxorubicin-loaded long-circulating liposomes modified with cancer-specific monoclonal antibody". Clinical Cancer Research, 2009; 15(6):1973-80. |
[11] | T. Elbayoumi *, "Nano-drug delivery systems in cancer therapy: gains, pitfalls and considerations in DMPK", J Therapeutic Delivery, 2010 1(2): 215-219. Invited Editorial (*corresponding author). |